Ren Goehrum - Biosyent CEO Chairman

RX Stock

CAD 11.70 0.45 4.00%

Insider

Ren Goehrum is CEO Chairman of Biosyent

Age	65
Address	2476 Argentia Road, Mississauga, ON, Canada, L5N 6M1
Phone	905 206 0013
Web	https://www.biosyent.com

Biosyent Management Efficiency

The company has return on total asset (ROA) of 0.1286 % which means that it generated a profit of $0.1286 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2088 %, meaning that it created $0.2088 on every $100 dollars invested by stockholders. Biosyent's management efficiency ratios could be used to measure how well Biosyent manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to 0.17 in 2024. Return On Capital Employed is likely to climb to 0.22 in 2024. At this time, Biosyent's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 5.9 M in 2024, whereas Other Current Assets are likely to drop slightly above 163.3 K in 2024.

Compare Biosyent to Peers

Predict price of Biosyent

Biosyent currently holds 1.22 M in liabilities. Biosyent has a current ratio of 9.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Biosyent until it has trouble settling it off, either with new capital or with free cash flow. So, Biosyent's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biosyent sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biosyent to invest in growth at high rates of return. When we think about Biosyent's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 12 records			INSIDER Age
	Jeff Martens	Knight Therapeutics	N/A
	Simon Smith	Covalon Technologies	N/A
	Janice Murray	Knight Therapeutics	N/A
	David Miller	Cipher Pharmaceuticals	N/A
	Ron Hebert	Covalon Technologies	N/A
	Bryan Jacobs	Cipher Pharmaceuticals	N/A
	Nicolas Sujoy	Knight Therapeutics	N/A
	Jason Gorel	Covalon Technologies	N/A
	Daniela Marino	Knight Therapeutics	N/A
	Michael Tremblay	Knight Therapeutics	N/A
	Chuoru Li	Cipher Pharmaceuticals	N/A
	BA BA	Knight Therapeutics	53

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BIOSYENT INC operates under Drug Manufacturers - Specialty Generic classification in Canada and is traded on TSX Venture Exchange. Biosyent (RX) is traded on TSX Venture Exchange in Canada and employs 5 people. Biosyent is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

	Return On Equity	0.21
	Return On Asset	0.13

Biosyent Leadership Team

Elected by the shareholders, the Biosyent's board of directors comprises two types of representatives: Biosyent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biosyent. The board's role is to monitor Biosyent's management team and ensure that shareholders' interests are well served. Biosyent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biosyent's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Alfred DSouza, Advisor
	Neelu Atwal, Director Resources
	Ren Goehrum, CEO Chairman
	Robert March, CFO, Senior Vice President - Finance
	Joost Mark, Vice Development

Biosyent Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biosyent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Number Of Shares Shorted

357

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Biosyent Stock Analysis

When running Biosyent's price analysis, check to measure Biosyent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosyent is operating at the current time. Most of Biosyent's value examination focuses on studying past and present price action to predict the probability of Biosyent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosyent's price. Additionally, you may evaluate how the addition of Biosyent to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC